Abstracts Archive - Page 2245 of 2425 - ACR Meeting Abstracts

Abstract Number: L1 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of CT-P13 (Infliximab biosimilar) over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13
Dae-Hyun Yoo¹, Nenad Prodanovic², Janusz Jaworski³, Pedro Miranda⁴, Edgar B. Ramiterre⁵, Allan Lanzon⁶, Asta Baranauskaite⁷, Piotr Wiland⁸, Carlos Abud-Mendoza⁹, Boycho Oparanov¹⁰, Svitlana Smiyan¹¹, YoungKi Son¹², Won Park¹³ and Ulf Müller-Ladner¹⁴, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Clinical Center Banja Luka, Banja Luka, Bosnia, ³Reumatika Centrum Reumatologi, Warszawa, Poland, ⁴Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ⁵Brokenshire Memorial Hospital, Davao City, Philippines, ⁶Mary Mediatrix Medical Center, Batangas, Philippines, ⁷Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania, ⁸Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁹Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosyi, Mexico, ¹⁰Military Medical Academy, Sofia, Bulgaria, ¹¹Municipal Institution of Ternopil Regional Council "Ternopil University Hospital", Ternopil, Ukraine, ¹²CELLTRION, Incheon, South Korea, ¹³Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ¹⁴Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany
Background/Purpose: CT-P13 is a biosimilar of infliximab (INX), approved by the European Medicines Agency. The objective of this open-label Phase 3 extension study was to…
Abstract Number: L6 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Co-Morbid Depression Receiving Concurrent Antidepressant Therapy: A Randomized, 2-Way Crossover, Double-Blind, Placebo-Controlled Study
Lesley M. Arnold¹, Piercarlo Sarzi-Puttini², Pierre Arsenault³, Tahira Khan⁴, Pritha Bhadra Brown⁵, Andrew Clair⁵, Joseph Driscoll⁴, Jaren Landen⁴ and Lynne Pauer⁴, ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Azienda Ospedaliera Polo Universitario L. Sacco, Milano, Italy, ³Département de Médecine de Famille, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and often associated with mood disorders including depression. Approximately 50–70% of FM patients have a lifetime…
Abstract Number: L5 • 2013 ACR/ARHP Annual Meeting
Improvement in High Density Lipoprotein Function in Early Rheumatoid Arthritis Patients Treated with Methotrexate Monotherapy or Combination Therapy in the Treatment of Early Rheumatoid Arthritis Trial
C. Charles-Schoeman¹, Yuen Yin Lee¹, Ani Shahbazian¹, David Elashoff², Xiaoyan Wong³, Jeffrey R. Curtis⁴, Iris Navarro-Millan⁵, Shuo Yang⁶, Lang Chen⁴, Stacey Cofield⁷, Larry W. Moreland⁸, Harold E. Paulus¹, James O' Dell⁹, Joan M. Bathon¹⁰, S. Louis Bridges Jr.¹¹ and Srinivasa T. Reddy¹², ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ³Medicine-Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁰Columbia University, New York, NY, ¹¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹²Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Abnormal function of high density lipoprotein (HDL) has been implicated as a potential mechanism for the increased cardiovascular disease (CVD) in patients with rheumatoid…
Abstract Number: L3 • 2013 ACR/ARHP Annual Meeting
A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
MC Genovese¹, Ronald van Vollenhoven², Bradley J. Bloom³, John G. Jiang³ and Nils Kinnman⁴, ¹Stanford University, Palo Alto, CA, ²Karolinska Institute, Stockholm, Sweden, ³Vertex Pharmaceuticals Incorporated, Cambridge, MA, ⁴Vertex Pharmaceuticals Incorporated, Eysins, Switzerland
Background/Purpose: VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). The objective of this 24-week, randomized, placebo-controlled, double-blind,…
Abstract Number: L12 • 2013 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Demonstrates Efficacy and Significantly Reduces Proinflammatory Cytokines in Patients with Active Longstanding Rheumatoid Arthritis with High Gonadotropin Levels: A Proof-of-Concept, Double-Blind, Randomized Trial
Anita Kåss^1,2, Ivana Hollan³, Peter Torjesen⁴, Hans Christian Gulseth⁵ and Øystein T. Førre⁶, ¹Faculty of Medicine, University of Oslo, Oslo, Norway, ²Dept. of Rheumatology, Betanien Hospital, Skien, Norway, ³Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Department of Endocrinology, Oslo University Hospital, Oslo, Norway, ⁵Rheumatology, Betanien Hospital, Skien, Norway, ⁶Oslo University Hospital, Oslo, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1). Inhibiting GnRH, by…
Abstract Number: L8 • 2013 ACR/ARHP Annual Meeting
Overexpression of Set1 at the Promoter Contributes to cAMP Response Element Modulator Alpha Overexpression in Systemic Lupus Erythematosus
Qing Zhang¹, Huilin Zhang², Hai Long¹, Jieyue Liao³, Ming Zhao¹, Xiangning Qiu¹ and Qianjin Lu¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Nursing Department, Second Xiangya Hospital, Central South University, Changsha, China, ³Department of Dermatology, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: In recent years, accumulating evidence has demonstrated that increased cAMP response element modulator α (CREMα) which contributes to IL-2 reduction and IL-17A overproduction in…
Abstract Number: L19 • 2013 ACR/ARHP Annual Meeting
Kellgren-Lawrence Grade (KL) 0 Vs. KL 1 Knees Differ in Their MRI Predictors of Subsequent Radiographic Osteoarthritis
C.Kent Kwoh¹, Ali Guermazi², Tomoko Fujii³, Robert M. Boudreau³, Michael Hannon⁴, Jason Grago⁴, David Hunter⁵, Felix Eckstein⁶ and Frank Roemer⁷, ¹Department of Medicine, The University of Arizona Arthritis Center, Tucson, AZ, ²Radiology, Boston University School of Medicine, Boston, MA, ³Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵University of Sydney, Sydney, Australia, ⁶Paracelsus Medical University, Salzburg, Austria, ⁷Klinikum Augsburg, Augsburg, Germany
Background/Purpose: Kellgren-Lawrence grade (KL) 1, defined by a questionable osteophyte and/or doubtful joint space narrowing, is thought to be an intermediate stage from non-OA (i.e.,…
Abstract Number: L20 • 2013 ACR/ARHP Annual Meeting
Association Between Germinal Center Formation in Labial Salivary Gland Biopsies and Predictors of Lymphoma Among Participants of the Sjӧgren’s International Collaborative Clinical Alliance (SICCA)
Annie Chou¹, Kimberly E. Taylor², Richard C.K. Jordan³, John S. Greenspan⁴, Troy E. Daniels⁴, Caroline H. Shiboski¹ and Lindsey A. Criswell^5,6, ¹Orofacial Sciences, University of California San Francisco, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Orofacial Sciences, Pathology, & Radiation Oncology, University of California San Francisco, San Francisco, CA, ⁴Orofacial Sciences & Pathology, University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁶University of California, San Francisco, Department of Medicine, San Francisco, CA
Background/Purpose: Sjӧgren’s Syndrome (SS) is a chronic autoimmune disease characterized by lymphocytic infiltration of the lacrimal and salivary glands causing dry eyes and dry mouth. …
Abstract Number: L9 • 2013 ACR/ARHP Annual Meeting
Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis: Radiographic, Clinical and Functional Comparison
Roy Fleischmann¹, E. B. Lee², S Hall³, B. E. Wilkinson⁴, John D. Bradley⁵, D. Gruben⁴, T. Koncz⁶, S. Krishnaswami⁷, G. Wallenstein⁶, S. H. Zwillich⁴ and R.F. van Vollenhoven⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Seoul National University, Seoul, South Korea, ³Cabrini Health and Monash University, Melbourne, Australia, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁸The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of RA. This Phase 3, 24-mo study (ORAL Start; NCT01039688) compared efficacy, including inhibition…
Abstract Number: L17 • 2013 ACR/ARHP Annual Meeting
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults with Autoimmune Disease
Lawrence McAdam¹, Michael Eberhardson², William Grainger³, Kim Papp⁴, Stephen Hall⁵, Tina Sterling⁶, Jon Stek⁶, Lei Pang⁶, Yanli Zhao⁶, Ivan Chan⁶, Richard Haupt⁶, Janie Parrino⁶ and Jeffrey Silber⁶, ¹Advanced Rheumatology, Infusion and Clinical Research Center, Thousand Oaks, CA, ²Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Neurological Physicians of Arizona, Gilbert, AZ, ⁴K. Papp Clinical Research,, Waterloo, ON, Canada, ⁵Emeritus Research, Malvern, Australia, ⁶Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Patients with autoimmune diseases are often immunocompromised, resulting in higher incidence of HZ than in immunocompetent individuals with significant morbidity and occasional mortality from…
Abstract Number: L16 • 2013 ACR/ARHP Annual Meeting
Kidney Resident B Cells and Plasmacytoid Dendritic Cells in Urine of Systemic Lupus Erythematosus patients
Eric Scott¹, Mary Anne Dooley² and Steve Clarke¹, ¹Microbiology/Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Title: Kidney resident B Cells and plasmacytoid dendritic cells (pDCs) in the urine of systemic lupus erythematosus (SLE) patients. Background/Purpose: Renal involvement remains the principal…
Abstract Number: L7 • 2013 ACR/ARHP Annual Meeting
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture Study
Alice Gottlieb¹, Richard Langley², Sandra Philipp³, Ruvie Martin⁴, Charis Papavassilis⁵ and Shephard Mpfofu⁵, ¹Tufts Medical Center, Boston, MA, ²Dalhousie University, Halifax, NS, Canada, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Novartis Pharma AG, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC; AIN457), a fully human anti–IL-17A monoclonal antibody, has demonstrated efficacy in phase 3 trials for treatment of plaque psoriasis and preliminary results…
Abstract Number: L18 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation of Bone Mineral Density Change in Women Receiving Depot Leuprolide Acetate during Cyclophosphamide Therapy for Severe Lupus Nephritis
Nathan Meier¹ and Mary Anne Dooley², ¹Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Cohort studies demonstrate that 11-83% of female patients receiving cyclophosphamide (CYC) for treatment of severe manifestations of SLE develop premature ovarian failure (POF), dependent…
Abstract Number: L10 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 2-Year Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Luis Puig², Alice B. Gottlieb³, Christopher T. Ritchlin⁴, Shu Li⁵, Yuhua Wang⁵, Alan Mendelsohn⁶, Michael Song⁵, Proton Rahman⁷ and Iain B. McInnes⁸, ¹UCSD School of Medicine, La Jolla, CA, ²Universitat Autònoma de Barcelona, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Janssen Research & Development, LLC., Spring House, PA, ⁶Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁷Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁸University of Glasgow, Glasgow, United Kingdom
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of subcutaneous UST 45/90 mg in patients with active psoriatic arthritis (PsA) through wk108 of the PSUMMIT 1 trial.…
Abstract Number: L14 • 2013 ACR/ARHP Annual Meeting
For Remission Induction with Glucocorticoid Bridging, Methotrexate Monotherapy Is As Effective As a Combination with Other Dmards, with Fewer Reported Side Effects: 4 Month Primary Outcome of Carera, a Randomized Induction Strategy and Treat to Target Trial in Early RA
Diederik De Cock¹, Sabrina Meyfroidt¹, Johan Joly², Kristien Van der Elst^2,3, Rene Westhovens^4,5 and Patrick Verschueren^2,6, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³Skeletal Biology and Engineering Research Center, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium, ⁴University of Leuven, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration; Rheumatology, University Hospital Leuven, Leuven, Belgium, ⁵Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ⁶1Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
Background/Purpose: Intensive combination therapy with glucocorticoids (GCs) is the most favorable treatment to benefit from the window of opportunity in early Rheumatoid Arthritis (eRA) but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].